A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")
about
Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review3,4-methylenedioxymethamphetamine (MDMA): current perspectivesThe safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyIs ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in othersFrom ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?From Autism to Eating Disorders and More: The Role of Oxytocin in Neuropsychiatric DisordersEmpathic accuracy and oxytocin after tryptophan depletion in adults at risk for depression.Fluorine in psychedelic phenethylaminesProsocial effects of oxytocin in two mouse models of autism spectrum disordersThe serotonin system in autism spectrum disorder: From biomarker to animal modelsNo evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activationHow MDMA's pharmacology and pharmacokinetics drive desired effects and harms.A window into the intoxicated mind? Speech as an index of psychoactive drug effectsThe nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats.Central oxytocin is involved in restoring impaired gastric motility following chronic repeated stress in miceThe neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice.Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptorContrasting Roles of Dopamine and Noradrenaline in the Motivational Properties of Social Play Behavior in Rats.The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.Defective oxytocin function: a clue to understanding the cause of autism?Effects of MDMA and Intranasal oxytocin on social and emotional processing.A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorderPlasma oxytocin concentrations following MDMA or intranasal oxytocin in humans'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content.Hypothalamic oxytocin mediates adaptation mechanism against chronic stress in rats.MDMA enhances emotional empathy and prosocial behaviorThe prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.Clinical applications of hallucinogens: A review.Acute Effects of the Novel Psychoactive Drug 2C-B on EmotionsEffects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting.Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin.Effects of acute doses of prosocial drugs methamphetamine and alcohol on plasma oxytocin levels.Effect of 8-hydroxy-2-(N,N-di-n-propylamino)tetralin and MDMA on the discriminative stimulus effects of the classical hallucinogen DOM in rats.Chronic cocaine exposure during pregnancy increases postpartum neuroendocrine stress responses.Effects of MDMA on sociability and neural response to social threat and social reward.Social housing conditions and oxytocin and vasopressin receptors contribute to ethanol conditioned social preference in female mice.Acute effects of MDMA on autonomic cardiac activity and their relation to subjective prosocial and stimulant effects.The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategiesHelping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.
P2860
Q22305514-D7887CC1-D6A9-4B62-BD30-1D95C6B516B6Q24602762-1689E1A7-31D6-487F-B0EB-2A8664328BAFQ24606265-6F7A3755-E7C1-486E-9913-A053208AE031Q24630561-A5FF0D2A-B379-4ED6-A8BF-045F77430F47Q24648383-E8CE5BF8-8176-481F-8D3C-9BAAD070F533Q26770469-59383903-85AF-4723-863B-F2518C326705Q27324786-7388F135-E7EB-4165-AE7F-69E8FA2FC92FQ28260924-EB979022-B637-46FD-B5E5-04E8B68CFC6EQ28386367-305D4723-5C60-4BA4-A6FE-164FF1BB8CE7Q28391614-29F78784-57FC-4EEF-BDB1-3B8EADD0B482Q28540131-A356DD65-B60A-460A-96B3-4C706CDC6265Q30357945-61095444-5D0E-45BA-BA58-503C4C760DB3Q30404060-4E8484AB-E0D0-43DA-A11A-99B82C2C406DQ30465634-E2F7695B-69A9-4B11-9E03-A02C6EE70C17Q30477733-ADD115D9-D763-4277-9F17-51FAD94FC701Q30504502-EA1412DF-46A2-4ED4-9C94-59A0FA79D6FAQ30544870-C83B2E22-B6DB-4C19-AFE0-FFAA1CB3941EQ30697151-78CC594D-645C-4494-94A7-8B4C232559D6Q33455500-2C81ACEC-FEF5-4D32-B61D-B11F83C3443DQ33511680-254B224C-9A00-46C6-A203-FB26D0CBC5C2Q33620569-9D01D1A3-B0BE-4719-9990-401AF626AE13Q33656107-93AF0FB0-B2EB-4D46-904C-375451430FB8Q33870495-8DC46286-8C44-4AE6-A1EC-C2A0046D655CQ34021568-C3D2E89B-8253-405C-8B7C-DCB2FDF9AF43Q34212107-2CA56AC9-59F9-4662-B648-7C14F5E6666FQ34375625-A65F1A98-5551-429E-9CBC-8161E71D51C0Q34495787-510897FB-A282-4230-8FEF-3E6040FB51F4Q34502080-1DBF3BDC-0DB4-4D6D-8378-936CE4D5104CQ34535259-9A1EA411-B7AE-482C-9CDA-702D4D13C991Q34674320-8B621887-0EB4-4945-B62C-BC2E045678A9Q34675745-5E35875E-87CE-43E6-B45C-B7508652A350Q35054947-15FCA937-0E7A-4503-A54C-E64AB9D30036Q35554326-F4A9D3E2-15F9-4C1C-B6B6-ADCDCF63E617Q35607891-63605979-0F63-47DE-8C9F-D94A9AB44CE6Q35856918-3298DCAB-E1EB-4D14-8E56-0761FB888818Q35895888-429D44C8-3D4B-4723-814B-0A23F0C6FD3FQ36103934-6DB8C978-7B49-4B67-AA68-783DD73D0D6BQ36253278-6F8423F8-32E5-4CA3-AD6A-AFD09045F526Q36353312-B05DABAD-4A7B-4F87-94FB-685FC5905366Q36685572-1AF01032-C929-495A-81BA-487B3324D0CE
P2860
A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")
description
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im Mai 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/05/11)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/05/11)
@nl
наукова стаття, опублікована в травні 2007
@uk
مقالة علمية (نشرت في 11-5-2007)
@ar
name
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@ast
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@en
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@nl
type
label
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@ast
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@en
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@nl
prefLabel
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@ast
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@en
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@nl
P2093
P1433
P1476
A role for oxytocin and 5-HT(1 ...... oxymethamphetamine ("ecstasy")
@en
P2093
G. E. Hunt
I. S. McGregor
J. L. Cornish
M. R. Thompson
P. D. Callaghan
P304
P356
10.1016/J.NEUROSCIENCE.2007.02.032
P407
P577
2007-05-11T00:00:00Z